Find Relief from Treatment-Resistant Depression (TRD) with SPRAVATO®

and have it be covered by your insurance

You are not alone. Millions of Americans suffer from treatment-resistant depression.

🧠
Major depressive disorder (MDD), also known as clinical depression, is one of the most common mental health disorders in the United States, affecting more than 21 million adults.
💭
Clinical depression symptoms may include depressed mood, loss of interest in daily activities, change in sleep, appetite or weight, fatigue, diminished concentration or slowed thoughts, feelings of worthlessness and/or suicidal ideation.
💊
When two or more antidepressants don’t provide relief for clinical depression, this is commonly known as treatment-resistant depression.
📊
According to a study, 1 in 3 people did not experience a reduction in their depressive symptoms when taking antidepressants alone.

Oral antidepressants may not work for everyone.

1 in 3

1 in 3 people did not experience a reduction in their depression symptoms when taking oral antidepressants alone.

86%

Based on a clinical study, 86% of patients do not achieve remission from depression symptoms by their third oral antidepressant.

If you’ve taken 2 or more oral antidepressants and still experience symptoms of depression, you may have treatment-resistant depression.

SPRAVATO® offers a different approach

SPRAVATO® is the only FDA-approved nasal spray for adults with treatment-resistant depression that can be taken with or without an oral antidepressant, giving you more options and flexibility.

SPRAVATO® reduces depression symptoms when oral antidepressants haven’t worked
SPRAVATO® works differently by acting on glutamate
Glutamate is a chemical messenger found in the brain that is thought to help balance well-being and depression
The exact way SPRAVATO® works is unknown

Scan here to watch top healthcare providers answer questions about SPRAVATO®

Visit SPRAVATO.com/asktheexperts

Data rates may apply.

You’ve decided to try SPRAVATO®. What’s next?

After you and your healthcare provider have decided SPRAVATO® is right for you – and you understand the benefits and risks – you can start planning for treatment at a certified treatment center.

With or Without an Antidepressant

Your healthcare provider will work with you to determine if SPRAVATO® should be taken with or without an oral antidepressant.

A Clear Dosing Schedule

For the first month, you’ll take SPRAVATO® twice per week, then once per week for the second month. After that, you and your provider will determine if treatment should be continued and will have the flexibility to decide your treatment frequency.

Start at Your Second Visit

You may start treatment as soon as your second visit to the SPRAVATO® treatment center.

Your First Visit to a Treatment Center

Your first visit to a certified SPRAVATO® treatment center will be a consultation. The treatment center will:

Receive your medical information from your healthcare provider.

Conduct its own assessment to confirm SPRAVATO® is an appropriate option.

Verify your insurance information as part of the eligibility confirmation.

Make sure to follow up with your healthcare provider after your treatment plan is built if you have questions.

What happens on your first day of treatment?

Self-Administration

2-Hour Observation

Plan Your Ride Home

Tips to Prepare

You Administer It Yourself, Under Supervision

You will administer SPRAVATO® nasal spray yourself under the supervision of a healthcare provider at a certified SPRAVATO® treatment center.

Our team walks you through every step, so you always know what to expect before, during and after the dose.

Your safety and comfort are monitored from the moment you arrive until the moment you leave.

What should you know about ongoing SPRAVATO® treatment?

An induction phase followed by maintenance sessions, tailored with your provider.

3: Ongoing Treatment

In a long-term clinical study, patients who stayed on SPRAVATO® were less likely to relapse.

SPRAVATO® Timeline

Induction Phase

Weeks 1-4

Two times per week

Maintenance Phase

Weeks 5-8

Once per week

Ongoing

Once per week or every 2 weeks

Dosing strength based on clinical judgment.

+248 clients

Schedule a phone Consultation

Not sure if you are a candidate to receive SPRAVATO®? Speak to our treatment specialist to ask any questions you may have and see if it is right for you.

When oral anti-depressants have you going in circles, SPRAVATO® may help you on the path to being yourself again.

Why Choose SPRAVATO®?

FDA-Approved
Nasal Spray

SPRAVATO® is the only FDA-approved nasal spray for adults with treatment-resistant depression, and it can be taken with or without an oral antidepressant.

Safe and Supervised

SPRAVATO® is self-administered at a certified treatment center under the supervision of a healthcare provider, with an observation period of at least 2 hours.

Effective for
Treatment-Resistant Depression

SPRAVATO® reduces depression symptoms when oral antidepressants haven’t worked — and it is covered by most major insurance plans.

What Research Says

The only FDA-approved nasal spray

SPRAVATO® is the only FDA-approved nasal spray for adults with treatment-resistant depression that can be taken with or without an oral antidepressant.

Source: SPRAVATO® Patient Brochure, Janssen Pharmaceuticals.

Frequently Asked
Questions

Who is a good candidate for Spravato treatment?

Spravato may be appropriate for adults who have tried two or more antidepressants without sufficient relief or who suffer from severe depression with suicidal thoughts. A medical evaluation is required to determine eligibility.

How does Spravato work?

Unlike traditional anti-depressants that target serotonin, Spravato works on the brain’s glutamate system, which can help form new neural connections and improve mood more rapidly.

What is Spravato?

Spravato (esketamine) is an FDA-approved nasal spray used in combination with an oral antidepressant to treat adults with treatment-resistant depression (TRD) and major depressive disorder (MDD) with suicidal thoughts or actions.

Your message has been sent!

Please allow us 24-48 hours to process it. You may also call us at (786)916-6073 for immediate assistance.

There was an error sending your message. Please try again.

Dr. Juan Oms, M.D.

Medical Director

Dr. Juan Oms, M.D., is a board-certified psychiatrist and experienced Medical Director specializing in advanced interventional psychiatry, including ketamine therapy and transcranial magnetic stimulation (TMS) for treatment-resistant depression. With extensive expertise in clinical psychiatry, substance use disorders, and healthcare administration, Dr. Oms has led pioneering mental health programs at prominent institutions such as Jackson Behavioral Health, Larkin Community Hospital, and AGAPE Network.